Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers

Objectives Pseudomonas aeruginosa is a major cause of severe healthcare-associated infections and often shows MDR phenotypes. Ceftolozane/tazobactam is a new cephalosporin/β-lactamase inhibitor combination with potent activity against P. aeruginosa. This survey was carried out to evaluate the susceptibility of P. aeruginosa, circulating in Italy, to ceftolozane/tazobactam and comparators and to investigate the molecular epidemiology of carbapenemase-producing strains. Methods Consecutive non-replicate P. aeruginosa clinical isolates (935) from bloodstream infections and lower respiratory tract infections were collected from 20 centres distributed across Italy from September 2013 to November 2014. Antimicrobial susceptibility testing was performed by broth microdilution and results were interpreted according to the EUCAST breakpoints. Isolates resistant to ceftolozane/tazobactam were investigated for carbapenemase genes by PCR, and for carbapenemase activity by spectrophotometric assay. WGS using an Illumina platform was performed on carbapenemase-producing isolates. Results Ceftolozane/tazobactam was the most active molecule, retaining activity against 90.9% of P. aeruginosa isolates, followed by amikacin (88.0% susceptibility) and colistin (84.7% susceptibility). Overall, 48 isolates (5.1%) were positive for carbapenemase genes, including blaVIM (n = 32), blaIMP (n = 12) and blaGES-5 (n = 4), while the remaining ceftolozane/tazobactam-resistant isolates tested negative for carbapenemase production. Carbapenemase producers belonged to 10 different STs, with ST175 (n = 12) and ST621 (n = 11) being the most common lineages. Genome analysis revealed different trajectories of spread for the different carbapenemase genes. Conclusions Ceftolozane/tazobactam exhibited potent in vitro activity against P. aeruginosa causing invasive infections in Italy. Carbapenemase production was the most common mechanism of resistance to ceftolozane/tazobactam.

[1]  A. Oliver,et al.  Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections , 2019, Clinical Microbiology Reviews.

[2]  B. Kreiswirth,et al.  Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation , 2017, Antimicrobial Agents and Chemotherapy.

[3]  M. Castanheira,et al.  Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015) , 2017, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[4]  M. Castanheira,et al.  Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015). , 2017, Journal of global antimicrobial resistance.

[5]  H. Seifert,et al.  In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany. , 2017, International journal of antimicrobial agents.

[6]  M. Castanheira,et al.  Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015 , 2017, Antimicrobial Agents and Chemotherapy.

[7]  A. Friedrich,et al.  Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. , 2017, The Lancet. Infectious diseases.

[8]  C. Thomson,et al.  Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia. , 2016, Annals of the American Thoracic Society.

[9]  R. Bonomo,et al.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  R. Cantón,et al.  In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study. , 2015, International journal of antimicrobial agents.

[11]  Gheyath K Nasrallah,et al.  Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies. , 2015, Future microbiology.

[12]  I. Broutin,et al.  Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins , 2015, Antimicrobial Agents and Chemotherapy.

[13]  Carlos Juan,et al.  The increasing threat of Pseudomonas aeruginosa high-risk clones. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[14]  James H. Jorgensen,et al.  Manual of Clinical Microbiology, 11th Edition , 2015 .

[15]  Jacques Corbeil,et al.  The Resistome of Pseudomonas aeruginosa in Relationship to Phenotypic Susceptibility , 2014, Antimicrobial Agents and Chemotherapy.

[16]  Ronald N. Jones,et al.  Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). , 2014, The Journal of antimicrobial chemotherapy.

[17]  Ronald N. Jones,et al.  Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). , 2014, The Journal of infection.

[18]  R. Kaas,et al.  Solving the Problem of Comparing Whole Bacterial Genomes across Different Sequencing Platforms , 2014, PloS one.

[19]  A. Oliver,et al.  Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC , 2014, Antimicrobial Agents and Chemotherapy.

[20]  Ronald N. Jones,et al.  Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012) , 2013, Antimicrobial Agents and Chemotherapy.

[21]  M. Toleman,et al.  Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. , 2013, The Lancet. Infectious diseases.

[22]  J. Karlowsky,et al.  In Vitro Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals in the CANWARD Study, 2007 to 2012 , 2013, Antimicrobial Agents and Chemotherapy.

[23]  J. Karlowsky,et al.  Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination , 2013, Drugs.

[24]  Sergey I. Nikolenko,et al.  SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing , 2012, J. Comput. Biol..

[25]  M. Falagas,et al.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[26]  A. Oliver,et al.  Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. , 2011, The Journal of antimicrobial chemotherapy.

[27]  P. Nordmann,et al.  Multiplex PCR for detection of acquired carbapenemase genes. , 2011, Diagnostic microbiology and infectious disease.

[28]  Ronald N. Jones,et al.  Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes , 2011, Antimicrobial Agents and Chemotherapy.

[29]  T. Kiser,et al.  Efflux Pump Contribution to Multidrug Resistance in Clinical Isolates of Pseudomonas aeruginosa , 2010, Pharmacotherapy.

[30]  A. Oliver,et al.  Activity of a New Antipseudomonal Cephalosporin, CXA-101 (FR264205), against Carbapenem-Resistant and Multidrug-Resistant Pseudomonas aeruginosa Clinical Strains , 2009, Antimicrobial Agents and Chemotherapy.

[31]  Nancy D. Hanson,et al.  Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms , 2009, Clinical Microbiology Reviews.

[32]  P. Nordmann,et al.  Diversity, Epidemiology, and Genetics of Class D β-Lactamases , 2009, Antimicrobial Agents and Chemotherapy.

[33]  P. Nordmann,et al.  Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum-{beta}-lactamase-producing Pseudomonas aeruginosa. , 2009, The Journal of antimicrobial chemotherapy.

[34]  G. Rossolini,et al.  First Countrywide Survey of Acquired Metallo-β-Lactamases in Gram-Negative Pathogens in Italy , 2008, Antimicrobial Agents and Chemotherapy.

[35]  A. Oliver,et al.  Nosocomial spread of Pseudomonas aeruginosa producing the metallo-beta-lactamase VIM-2 in a Spanish hospital: clinical and epidemiological implications. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[36]  P. Lebecque,et al.  Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[37]  Robert A. Bonomo,et al.  Extended-Spectrum (cid:2) -Lactamases: a Clinical Update , 2005 .

[38]  C. Giske,et al.  Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates , 2005, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[39]  D. Livermore,et al.  Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  N. Gotoh,et al.  Carbapenem Resistance Mechanisms in Pseudomonas aeruginosa Clinical Isolates , 2001, Antimicrobial Agents and Chemotherapy.

[41]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[42]  N. Masuda,et al.  Substrate Specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM Efflux Pumps in Pseudomonas aeruginosa , 2000, Antimicrobial Agents and Chemotherapy.

[43]  S. Lory,et al.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen , 2000, Nature.

[44]  Albert Balows,et al.  Manual of Clinical Microbiology, 7th ed. , 2000 .

[45]  G. Cornaglia,et al.  Cloning and Characterization of blaVIM, a New Integron-Borne Metallo-β-Lactamase Gene from a Pseudomonas aeruginosa Clinical Isolate , 1999, Antimicrobial Agents and Chemotherapy.

[46]  T. Köhler,et al.  Carbapenem Activities against Pseudomonas aeruginosa: Respective Contributions of OprD and Efflux Systems , 1999, Antimicrobial Agents and Chemotherapy.

[47]  Ellen Jo Baron,et al.  Manual of clinical microbiology , 1975 .

[48]  J. Brożek,et al.  Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  R. Evans.  European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[50]  M. Kollef,et al.  The Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections , 2012, Drugs.

[51]  G. Rossolini,et al.  Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[52]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .